Flagship, Arch cut their losses, quietly shutter Ensemble Therapeutics as pipeline plans fizzle out
Here’s another cautionary tale to keep in mind during the go-go years of the US biotech scene.
After getting started with more than $40 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
